Royal Free London NHS Foundation Trust, London, UK
Royal Marsden Hospital & Institute of Cancer Research, London, UK.
Clin Med (Lond). 2017 Oct;17(5):462-468. doi: 10.7861/clinmedicine.17-5-462.
This article discusses the important role of nuclear medicine imaging and therapy in the management of neuroendocrine tumours (NETs). Somatostatin receptor scintigraphy has a high impact on patient management versus conventional imaging. Molecular radiotherapy is an important part of the management of patients with NETs. Selection of patients for molecular radiotherapy in NETs is based on uptake on their radionuclide imaging study. The imaging agent has the same mechanism of uptake as the therapeutic agent. Thus, the imaging study preselects patients that are likely to concentrate radiation within their tumours.
本文讨论了核医学成像和治疗在神经内分泌肿瘤（NETs）管理中的重要作用。生长抑素受体闪烁显像对患者管理的影响明显高于常规成像。分子放疗是 NETs 患者管理的重要组成部分。NETs 患者进行分子放疗的选择基于其放射性核素成像研究的摄取。成像剂与治疗剂具有相同的摄取机制。因此，成像研究预先选择了那些可能在肿瘤内集中辐射的患者。
